AU2015301596B2 - Anti-methanogenic compositions and uses thereof - Google Patents

Anti-methanogenic compositions and uses thereof Download PDF

Info

Publication number
AU2015301596B2
AU2015301596B2 AU2015301596A AU2015301596A AU2015301596B2 AU 2015301596 B2 AU2015301596 B2 AU 2015301596B2 AU 2015301596 A AU2015301596 A AU 2015301596A AU 2015301596 A AU2015301596 A AU 2015301596A AU 2015301596 B2 AU2015301596 B2 AU 2015301596B2
Authority
AU
Australia
Prior art keywords
release
modified
weight
formulation
lovastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301596A
Other languages
English (en)
Other versions
AU2015301596A1 (en
Inventor
Steve Kanzer
Ruchi Mathur
Mark Pimentel
Vince WACHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Theriva Biologics Inc
Original Assignee
Cedars Sinai Medical Center
Synthetic Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Synthetic Biologics Inc filed Critical Cedars Sinai Medical Center
Publication of AU2015301596A1 publication Critical patent/AU2015301596A1/en
Application granted granted Critical
Publication of AU2015301596B2 publication Critical patent/AU2015301596B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2015301596A 2014-08-13 2015-08-13 Anti-methanogenic compositions and uses thereof Active AU2015301596B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462036948P 2014-08-13 2014-08-13
US62/036,948 2014-08-13
US201462043789P 2014-08-29 2014-08-29
US201462043649P 2014-08-29 2014-08-29
US62/043,789 2014-08-29
US62/043,649 2014-08-29
US201562141355P 2015-04-01 2015-04-01
US62/141,355 2015-04-01
PCT/US2015/045140 WO2016025762A1 (en) 2014-08-13 2015-08-13 Anti-methanogenic compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2015301596A1 AU2015301596A1 (en) 2017-02-02
AU2015301596B2 true AU2015301596B2 (en) 2020-04-16

Family

ID=55301332

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015301596A Active AU2015301596B2 (en) 2014-08-13 2015-08-13 Anti-methanogenic compositions and uses thereof

Country Status (12)

Country Link
US (5) US9956292B2 (enExample)
EP (1) EP3179983A4 (enExample)
JP (1) JP6667526B2 (enExample)
KR (1) KR102425303B1 (enExample)
CN (1) CN106687107B (enExample)
AU (1) AU2015301596B2 (enExample)
BR (1) BR112017002761A2 (enExample)
CA (1) CA2955666A1 (enExample)
IL (1) IL250568B (enExample)
MX (1) MX2017001971A (enExample)
RU (1) RU2697851C2 (enExample)
WO (1) WO2016025762A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903493C (en) 2013-03-15 2022-05-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
AU2015301596B2 (en) 2014-08-13 2020-04-16 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
KR20240039186A (ko) 2015-06-03 2024-03-26 트리아스텍 인코포레이티드 제형 및 이의 용도
US10219518B2 (en) * 2015-09-18 2019-03-05 Environmental Intellectual Property, Inc. Inhibition of methanogenesis to control wood boring insects and pestilence
US20190277833A1 (en) * 2016-05-19 2019-09-12 Synthetic Biologics, Inc. Anti-methanogenic compositions
US20200390742A1 (en) * 2016-06-21 2020-12-17 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses
AU2017378398B2 (en) * 2016-12-14 2023-02-02 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
KR102616436B1 (ko) * 2016-12-14 2023-12-27 비오라 쎄라퓨틱스, 인크. Tnf 저해제로의 위장관 질환의 치료
CA3045931A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
KR20190107712A (ko) * 2017-01-26 2019-09-20 트리아스텍 인코포레이티드 특정 위장 부위에서의 제어 방출의 투여 형태
IL319156A (en) * 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
CN113329741A (zh) * 2018-09-10 2021-08-31 阿根塔创新有限公司 递送装置中的缓释制剂
BR112022005755A2 (pt) * 2019-10-09 2022-06-21 Scherer Technologies Llc R P Formulações de cápsula de gel macio não animal, métodos de preparação, e métodos de uso das mesmas
US11529310B2 (en) 2020-12-08 2022-12-20 Ruminant Biotech Corp Limited Devices and methods for delivery of substances to animals
WO2023069904A1 (en) * 2021-10-19 2023-04-27 Cedars-Sinai Medical Center Daily fasting methane to detect intestinal methanogen overgrowth and monitor treatment response
WO2023119207A1 (en) * 2021-12-23 2023-06-29 Fonterra Co-Operative Group Limited Use of lactic acid bacteria to improve feed efficiency
WO2024006531A1 (en) 2022-07-01 2024-01-04 Arkea Bio Corp. Compositions and methods for reducing deleterious atmospheric gas emissions from flooded ecosystems
CN121712489A (zh) * 2023-08-15 2026-03-20 赢创运营有限公司 一种用于在回肠和结肠递送剂型的肠溶包衣硬壳胶囊
AU2024327436A1 (en) 2023-08-24 2026-03-05 Synergraze Inc. Methods and compositions for improving feed-efficiency in animals and reducing enteric methane emissions
US12448600B2 (en) 2023-08-24 2025-10-21 Synergraze Inc. Extraction of antimethanogenic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225202A (en) 1880-03-02 Clothes-slide
GB423083A (en) 1934-05-22 1935-01-24 Hugh Edwin Johnstone Peake Improvements in and relating to the manufacture of fermented beverages and medicinalpreparations
JPS60133852A (ja) 1983-12-23 1985-07-17 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai 新規な納豆製品
DE3718638A1 (de) 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH03275630A (ja) 1990-03-23 1991-12-06 Hayashikane Sangyo Kk 肝機能改善剤及び肝機能改善食品又は飲料
US6036950A (en) 1993-10-19 2000-03-14 Commonwealth Scientific And Industrial Research Organisation Method for improving utilisation of nutrients by ruminant or ruminant-like animals
US5447850A (en) 1994-01-31 1995-09-05 Mccann; James L. Method of producing methane from organic waste
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
JP3010007B2 (ja) 1995-05-22 2000-02-14 ビオフェルミン製薬株式会社 配合下剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
GB9711962D0 (en) 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
CN1119154C (zh) 1998-01-20 2003-08-27 上海信谊药业有限公司 双歧三联活菌制剂及制备方法
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US5985907A (en) 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
US6328959B1 (en) 1998-09-18 2001-12-11 The United States Of America As Represented By The Secretary Of The Navy Intestinal hydrogen removal using hydrogen-metabolizing microbes
WO2000033821A1 (en) * 1998-12-07 2000-06-15 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
IL149422A0 (en) 1999-11-03 2002-11-10 Smith Howard J & Ass Pty Ltd Oral pharmaceutical compositions for liver therapy
DE10085183T1 (de) 1999-11-08 2002-10-24 Andrx Corp Zubereitung eines HMG-COA Reduktase-Inhibitors mit verlängerter Freisetzungsdauer
AU2001269015B2 (en) 2000-06-13 2004-10-14 Unilever Plc Non-viable lactobacillus containing food product
US6299774B1 (en) 2000-06-26 2001-10-09 Jack L. Ainsworth Anaerobic digester system
JP2004535433A (ja) * 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
CA2486585C (en) 2002-05-20 2012-07-10 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
EP1523320B1 (en) 2002-07-18 2011-08-31 Agricultural Research Council Megasphaera elsdenii strain and its uses
JP2006503023A (ja) 2002-09-03 2006-01-26 バイオヴェイル ラボラトリーズ インコーポレイテッド スタチン薬物の放出調節ための医薬品製剤および方法
MXPA05002095A (es) * 2002-09-03 2005-06-06 Biovail Lab Int Srl Formulaciones farmaceuticas de pravastatina y metodos de su uso.
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
CA2541753A1 (en) 2003-07-10 2005-01-20 Michelle Alfa Combination therapy for gastroenteric diseases caused by microorganisms
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
AU2003289546A1 (en) 2003-12-16 2005-07-05 Uk Chemipharm Co., Ltd. Process for preparing simvastatin.
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2005115380A2 (en) 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
US20060111436A1 (en) 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
WO2006102350A1 (en) * 2005-03-23 2006-09-28 Washington University In St. Louis The use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
EP2079448A2 (en) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
WO2008151032A2 (en) 2007-05-31 2008-12-11 Washington University In St. Louis Arrays and methods comprising m. smithii gene products
MX354786B (es) * 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US7970905B2 (en) 2008-07-03 2011-06-28 International Business Machines Corporation Method, system and computer program product for server selection, application placement and consolidation planning of information technology systems
CN102369275A (zh) 2009-02-02 2012-03-07 卓莫赛尔公司 新型细胞系和方法
UY32802A (es) 2009-07-23 2011-01-31 Provimi Holding B V Composiciones para reducir la metanogénesis gastrointestinal en rumiantes
WO2011103123A2 (en) 2010-02-16 2011-08-25 Arizona Technology Enterprises Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
CN103230593A (zh) * 2012-10-30 2013-08-07 辽宁亿灵科创生物医药科技有限公司 一种治疗胃肠疾病的药物组合物
WO2014110090A1 (en) * 2013-01-08 2014-07-17 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法
CA2903493C (en) 2013-03-15 2022-05-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
AU2015301596B2 (en) 2014-08-13 2020-04-16 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20200390742A1 (en) 2016-06-21 2020-12-17 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Also Published As

Publication number Publication date
KR102425303B1 (ko) 2022-07-25
CA2955666A1 (en) 2016-02-18
JP2017528516A (ja) 2017-09-28
MX2017001971A (es) 2017-09-15
US20200323781A1 (en) 2020-10-15
EP3179983A1 (en) 2017-06-21
IL250568B (en) 2021-05-31
RU2697851C2 (ru) 2019-08-21
KR20170041769A (ko) 2017-04-17
US11344501B2 (en) 2022-05-31
CN106687107A (zh) 2017-05-17
US10668159B2 (en) 2020-06-02
US9956292B2 (en) 2018-05-01
US20180289816A1 (en) 2018-10-11
US20160045604A1 (en) 2016-02-18
EP3179983A4 (en) 2018-01-10
BR112017002761A2 (pt) 2017-12-19
AU2015301596A1 (en) 2017-02-02
US20230036151A1 (en) 2023-02-02
WO2016025762A1 (en) 2016-02-18
US10328151B2 (en) 2019-06-25
CN106687107B (zh) 2020-12-25
RU2017106896A (ru) 2018-09-13
IL250568A0 (en) 2017-03-30
JP6667526B2 (ja) 2020-03-18
RU2017106896A3 (enExample) 2019-03-19
US20190328885A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US20230036151A1 (en) Anti-methanogenic compositions and uses thereof
US20230398093A1 (en) Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20200390742A1 (en) Clinically efficacious anti-methanogenic compositions and uses
KR20150046310A (ko) 완화제 조성물 및 변비 및 관련 위장관 질병 및 증상 치료를 위한 방법
US20200360468A1 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
JP7651620B2 (ja) 経口リファマイシンｓｖ組成物
US20190277833A1 (en) Anti-methanogenic compositions
EP3024461B1 (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
RU2793319C2 (ru) Композиции рифамицина sv для перорального применения
Saeed et al. The Gut Microbiota’s Role in Drug Absorption, Metabolism and Efficacy: Implications for Personalized Medicine
HK40110949A (en) Oral rifamycin sv compositions
HK40036103A (en) Oral rifamycin sv compositions
HK40036103B (en) Oral rifamycin sv compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)